Gerd Ritter, Ph.D.
Ludwig Institute for Cancer Research
New York, NY
Dr. Gerd Ritter is developmental research director at the Ludwig Institute for Cancer Research and a member of various steering committees for Institute academic and industrial partnerships and collaborations on the development of cancer immunotherapies.
Dr. Ritter previously held Ludwig appointments of associate member at the Ludwig New York Branch at Memorial Sloan-Kettering Cancer Center, where he also served as associate director, and of assistant director of the Office of Clinical Trials Management. He is currently a member of the CRI/Ludwig CVC Trials Network Management Team and a member of the Executive Committee of the CRI Cancer Immunotherapy Consortium.
Dr. Ritter has made many contributions to antibody-based and vaccine-based human cancer immunotherapy including human cancer antigen discovery and characterization, clinical cancer vaccine and antibody construction and development, procurement of clinical investigational agents and immunological monitoring technologies. His research has been published in more than 150 peer-reviewed scientific articles.
Dr. Ritter received his doctorate in human biology from the University of Marburg, Germany, trained as a postdoctoral fellow in human cancer immunology at Memorial-Sloan-Kettering Cancer Center in New York, was a research group leader in immunology at Fidia Research Laboratories, Abano Terme, Italy, and had held faculty positions at Weill Cornell Medical College and the Ludwig Institute for Cancer Research in New York.